ICMR refuses using Molnupiravir for COVID treatment, pulmonologists disagree
Dr Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
COVID-19 Updates
Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction…
India to become hub for COVID-19 antiviral generic drugs: Fitch
Increased access to Molnupiravir will keep hospitalisations and deaths in India to a manageable level as Omicron infections rise,…
Covaxin booster dose study shows promising results
The phase-II, double-blind, randomised controlled Covaxin trial demonstrated long-term safety with no serious adverse events
People may need another COVID-19 vaccine booster shot in fall of 2022: Moderna CEO
Moderna, which benefits by repeat inoculations, during its third quarter earnings results said that commercial booster market…
J&J says single dose protects against breakthrough COVID-19 for up to six months
The study, sponsored by the vaccine developer, was conducted between 1st January and 7th September last year, before the Omicron…
MSN to launch generic anti-COVID pill Molnupiravir under ‘Molulow’ brand
Molulow will come as a pack of 4×10 capsule strips with each capsule in 200 mg strength
Gavi and Bharat Biotech discuss possible COVAX use of Covaxin
About 180 million Covaxin doses have been administered in India and more than three million doses have been exported or donated
Lupin launches Molnupiravir under brand name Molnulup to treat COVID-19
Clinical data suggests that it is effective on patients with co-morbidities
Preparing for 2022: Lessons and Strategies
As we enter into a new year, pharma industry’s stakeholders talk about various strategies to implement the lessons learnt from the…
No paracetamol, painkillers recommended after Covaxin jab: Bharat Biotech
Medication is recommended only after consultation with a physician, the vaccine maker said
Aurobindo Pharma rolls out Molnaflu to treat adult COVID-19 patients
The pill is available pan-India across all major metros and towns
Leiden University Medica Center and Intravacc to start clinical trial with new intranasal corona…
Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
Pfizer to supply US with 10 million more courses of COVID-19 pills
The White House now expects some four million treatment courses of the pills to be available by the end of January and 10 million…
Entod Pharmaceuticals set to launch Molentod for treating COVID-19
Molentod will be available at retail chemists, pharmacy chains, hospitals and online stores across India at an affordable price to…
Dr Reddy’s to launch generic COVID-19 Merck drug at about 50 cents a pill
The overall cost for a patient treated with a five-day course of 40 capsules of the generic drug, to be sold under brand name…
Interval between Moderna COVID-19 vaccine second shot and booster still six months: FDA
"Right now, if you got J&J, you get a booster after two months, if you got Pfizer as your primary series you can get a booster…
Britain approves Pfizer’s anti-viral COVID-19 pill Paxlovid
Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain's Medicines and…
Novavax submits final data to US FDA as prerequisite to EUA application request for COVID-19 vaccine
Novavax has filed the complete CMC data package, which leverages Novavax's manufacturing partnership with the Serum Institute of…
Emcure Pharmaceuticals to launch oral COVID-19 drug in a week’s time in India
A toll-free helpline to be set up to help doctors and patients